Specialty Pharma Journal Specialty, Precision & Technology
Gaithersburg, MD and Woburn, MA, November 29, 2016 – MedImmune, the global biologics research and development arm of AstraZeneca, and Abpro, an integrated life sciences company at the forefront of synthetic biology, today announced they have entered into a collaborative agreement to advance the development of a preclinical, novel bispecific …
Tag Archives: VEGF
November, 2016
-
16 November
Amgen and Allergan Submit BLA for Biosimilar Candidate to Avastin
THOUSAND OAKS, Calif., Nov. 15, 2016 /PRNewswire/ — Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 215, a biosimilar candidate to Avastin® (bevacizumab). ABP 215 is the most advanced of the four …
March, 2016
-
25 March
Bayer and Regeneron Partner to Develop Novel Combination Therapy for Eye Diseases
TARRYTOWN, N.Y., March 24, 2016 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer will jointly develop a combination therapy of the angiopoietin2 (Ang2) antibody nesvacumab and the vascular endothelial growth factor (VEGF) trap aflibercept, for the treatment of serious eye diseases. Two separate Phase 2 clinical studies are evaluating …